Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.77 Billion CNY | -8.4% |
| 2022 | 6.3 Billion CNY | 29.76% |
| 2021 | 4.85 Billion CNY | 12.77% |
| 2020 | 4.3 Billion CNY | 46.27% |
| 2019 | 2.94 Billion CNY | 9.38% |
| 2018 | 2.69 Billion CNY | 58.81% |
| 2017 | 1.69 Billion CNY | 68.51% |
| 2016 | 1 Billion CNY | 25.94% |
| 2015 | 798.56 Million CNY | 94.83% |
| 2014 | 409.87 Million CNY | 21.86% |
| 2013 | 336.35 Million CNY | 11.15% |
| 2012 | 302.6 Million CNY | 15.44% |
| 2011 | 262.12 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 6.75 Billion CNY | 1.29% |
| 2024 Q1 | 6.67 Billion CNY | 15.63% |
| 2024 Q2 | 6.66 Billion CNY | -0.15% |
| 2023 Q3 | 5.76 Billion CNY | -1.33% |
| 2023 Q1 | 5.91 Billion CNY | -6.08% |
| 2023 Q2 | 5.84 Billion CNY | -1.23% |
| 2023 FY | 5.77 Billion CNY | -8.4% |
| 2023 Q4 | 5.77 Billion CNY | 0.08% |
| 2022 Q3 | 6.27 Billion CNY | -2.24% |
| 2022 FY | 6.3 Billion CNY | 29.76% |
| 2022 Q2 | 6.41 Billion CNY | -3.45% |
| 2022 Q1 | 6.64 Billion CNY | 36.84% |
| 2022 Q4 | 6.3 Billion CNY | 0.47% |
| 2021 Q1 | 4.45 Billion CNY | 3.57% |
| 2021 FY | 4.85 Billion CNY | 12.77% |
| 2021 Q3 | 4.68 Billion CNY | -2.97% |
| 2021 Q2 | 4.82 Billion CNY | 8.18% |
| 2021 Q4 | 4.85 Billion CNY | 3.72% |
| 2020 Q1 | 3.57 Billion CNY | 21.38% |
| 2020 Q3 | 4.22 Billion CNY | 9.62% |
| 2020 Q4 | 4.3 Billion CNY | 2.04% |
| 2020 FY | 4.3 Billion CNY | 46.27% |
| 2020 Q2 | 3.84 Billion CNY | 7.73% |
| 2019 Q1 | 2.78 Billion CNY | 3.56% |
| 2019 FY | 2.94 Billion CNY | 9.38% |
| 2019 Q4 | 2.94 Billion CNY | 4.06% |
| 2019 Q2 | 2.8 Billion CNY | 0.48% |
| 2019 Q3 | 2.82 Billion CNY | 1.01% |
| 2018 Q4 | 2.69 Billion CNY | 6.71% |
| 2018 Q2 | 2.61 Billion CNY | 46.99% |
| 2018 Q1 | 1.77 Billion CNY | 4.77% |
| 2018 FY | 2.69 Billion CNY | 58.81% |
| 2018 Q3 | 2.52 Billion CNY | -3.37% |
| 2017 Q1 | 1.21 Billion CNY | 21.12% |
| 2017 FY | 1.69 Billion CNY | 68.51% |
| 2017 Q4 | 1.69 Billion CNY | 6.73% |
| 2017 Q3 | 1.58 Billion CNY | 17.03% |
| 2017 Q2 | 1.35 Billion CNY | 11.38% |
| 2016 FY | 1 Billion CNY | 25.94% |
| 2016 Q3 | 925.09 Million CNY | 5.01% |
| 2016 Q2 | 880.93 Million CNY | 8.23% |
| 2016 Q1 | 813.96 Million CNY | 1.93% |
| 2016 Q4 | 1 Billion CNY | 8.72% |
| 2015 Q2 | 745.13 Million CNY | 77.68% |
| 2015 FY | 798.56 Million CNY | 94.83% |
| 2015 Q3 | 771.13 Million CNY | 3.49% |
| 2015 Q4 | 798.56 Million CNY | 3.56% |
| 2015 Q1 | 419.36 Million CNY | 2.31% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 409.87 Million CNY | 0.0% |
| 2014 FY | 409.87 Million CNY | 21.86% |
| 2013 FY | 336.35 Million CNY | 11.15% |
| 2012 FY | 302.6 Million CNY | 15.44% |
| 2011 FY | 262.12 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 17.93 Billion CNY | 67.826% |
| Hangzhou Tigermed Consulting Co., Ltd. | 29.69 Billion CNY | 80.565% |
| Dirui Industrial Co.,Ltd. | 3.32 Billion CNY | -73.807% |
| Beijing Strong Biotechnologies, Inc. | 5.17 Billion CNY | -11.515% |
| Medicalsystem Biotechnology Co., Ltd. | 3.48 Billion CNY | -65.417% |
| Maccura Biotechnology Co.Ltd | 8.11 Billion CNY | 28.913% |
| Guangdong Hybribio Biotech Co.,Ltd. | 5.72 Billion CNY | -0.802% |
| BGI Genomics Co., Ltd. | 13.61 Billion CNY | 57.601% |
| Amoy Diagnostics Co., Ltd. | 1.93 Billion CNY | -198.298% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 2.98 Billion CNY | -93.237% |